Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 29, 2020. The registrant is a Delaware corporation with its principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing reports a specific capital event rather than comprehensive financial statements:
- Proceeds Raised: Approximately $1.45 million.
- Source of Funds: Exercise of common stock purchase warrants by holders.
- Exercise Price: $1.56 per share.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide clear values for these metrics; it only details the specific warrant exercise proceeds.
Material Changes
The material change reported is the increase in cash proceeds of $1.45 million resulting from the warrant exercises on January 29, 2020. No comparative period data or prior period financial metrics are included in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the announcement of the warrant exercise. The document serves solely to disclose the transaction and includes a press release as Exhibit 99.1.
Investor Verification Checklist
- Verify the exact number of shares issued upon exercise of the warrants (not explicitly stated in the summary text, though proceeds and price are known).
- Confirm the impact of this $1.45 million cash infusion on the company's total liquidity and runway.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the warrant holders or future capital plans.
- Note the discrepancy between the requested company name (Cardiff Oncology) and the filing registrant (Trovagene).